BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang R, Hao Y, Zhang J, Wu C. Interferon-alpha plus adefovir combination therapy versus interferon-alpha monotherapy for chronic hepatitis B treatment: A meta-analysis. Hepatol Res 2013;43:1040-51. [PMID: 23356962 DOI: 10.1111/hepr.12058] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Yano Y, Seo Y, Hayashi H, Hatazawa Y, Hirano H, Minami A, Kawano Y, Saito M, Ninomiya T, Sugano M, Yamada H, Kitajima N, Yoon S, Hayashi Y. Factors associated with the decrease in hepatitis B surface antigen titers following interferon therapy in patients with chronic hepatitis B: Is interferon and adefovir combination therapy effective? Biomed Rep 2017;7:257-62. [PMID: 28819561 DOI: 10.3892/br.2017.944] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 Li H, Wang H, Peng C, Zheng X, Liu J, Weng ZH, Yang DL. Predictors for efficacy of combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B. J Huazhong Univ Sci Technolog Med Sci 2017;37:547-55. [PMID: 28786051 DOI: 10.1007/s11596-017-1771-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
3 Song Q, Meng Y, Wang Y, Li M, Zhang J, Xin S, Wang L, Shan F. Maturation inside and outside bone marrow dendritic cells (BMDCs) modulated by interferon-α (IFN-α). Int Immunopharmacol. 2013;17:843-849. [PMID: 24095953 DOI: 10.1016/j.intimp.2013.09.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
4 Lin FC, Young HA. Interferons: Success in anti-viral immunotherapy. Cytokine Growth Factor Rev. 2014;25:369-376. [PMID: 25156421 DOI: 10.1016/j.cytogfr.2014.07.015] [Cited by in Crossref: 138] [Cited by in F6Publishing: 121] [Article Influence: 17.3] [Reference Citation Analysis]
5 Zhang K, Cao H, Liang J, Shu X, Sun H, Li G, Xu Q. CONSORT: Effects of adding adefovirdipivoxil to peginterferon alfa-2a at different time points on HBeAg-positivepatients: A prospective, randomized study. Medicine (Baltimore). 2016;95:e4471. [PMID: 27495085 DOI: 10.1097/md.0000000000004471] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
6 Wang D, Fu B, Shen X, Guo C, Liu Y, Zhang J, Sun R, Ye Y, Li J, Tian Z, Wei H. Restoration of HBV-specific CD8+ T-cell responses by sequential low-dose IL-2 treatment in non-responder patients after IFN-α therapy. Signal Transduct Target Ther 2021;6:376. [PMID: 34737296 DOI: 10.1038/s41392-021-00776-0] [Reference Citation Analysis]
7 Zhou J, Wu X, Wei W, You H, Jia J, Kong Y. A Meta-Analysis of the Efficacy of Interferon Monotherapy or Combined with Different Nucleos(t)ide Analogues for Chronic Hepatitis B. Int J Environ Res Public Health 2016;13:E730. [PMID: 27455288 DOI: 10.3390/ijerph13070730] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
8 Xie QL, Zhu Y, Wu LH, Fu LL, Xiang Y. The Efficacy and Safety of Entecavir and Interferon Combination Therapy for Chronic Hepatitis B Virus Infection: A Meta-Analysis. PLoS One. 2015;10:e0132219. [PMID: 26226455 DOI: 10.1371/journal.pone.0132219] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
9 Friedman A, Siewe N. Chronic hepatitis B virus and liver fibrosis: A mathematical model. PLoS One 2018;13:e0195037. [PMID: 29634771 DOI: 10.1371/journal.pone.0195037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
10 Liu YH, Wu T, Sun N, Wang GL, Yuan JZ, Dai YR, Zhou XH. Combination therapy with pegylated interferon alpha-2b and adefovir dipivoxil in HBeAg-positive chronic hepatitis B versus interferon alone: a prospective, randomized study. J Huazhong Univ Sci Technolog Med Sci 2014;34:542-7. [PMID: 25135724 DOI: 10.1007/s11596-014-1312-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]